Drugs / Begelomab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02411084 | Feb 2016 → Jul 2017 | acute graft versus host disease | Adienne SA | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Begelomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02411084 ↗ |
| Known as | Begedina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833357 ↗ |
| Known as | BT 5/9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833357 ↗ |
| Known as | SAND-26 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833357 ↗ |
| Action | Inhibit | “BEGEDINA® reduces the activity of CD26 in these cells and inhibits the immune response” NCT02411084 ↗ |
| Modality | Monoclonal antibody | “murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26” NCT02411084 ↗ |
| Route | Intravenous | “Dose is 2.7 mg/m2/day i.v. infusion” NCT02411084 ↗ |
| Target | DPP4 | “monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4)” NCT02411084 ↗ |